FDA approves Takeda’s narcolepsy drug and the first mRNA flu vaccine
The U.S. Food and Drug Administration has granted approval to a new narcolepsy treatment developed by Takeda, marking a significant addition to the therapeutic options for the sleep disorder.
In a separate decision, the agency also approved the first mRNA‑based influenza vaccine, representing a milestone for mRNA technology beyond COVID‑19 applications.
The approvals were highlighted alongside other biotech news, including a tragic death in a gene‑therapy trial in China and promising early results from a fecal‑pill approach for peanut allergy.
The article also noted that biotech investor Greg Verdine reported a series of recent successes, underscoring ongoing momentum in the sector.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Two FDA approvals — a new drug and a new vaccine”
read at STAT ↗
comments(0)
5-min edit window · permanent after that